Alirocumab is recommended as an option for treating primary hypercholesterolaemia or mixed dyslipidaemia, only if:
Evolocumab is recommended as an option for treating primary hypercholesterolaemia or mixed dyslipidaemia, only if:
Low-density lipoprotein cholesterol concentrations above which alirocumab and evolocumab is recommended
Without CVD | CVD - High risk of CVD1 | CVD - Very High risk of CVD2 | |
Primary non-familial hypercholesterolaemia or mixed dyslipidaemia | Not recommended at any LDL-C concentration | Recommended only if LDL-C concentration is persistently above 4.0 mmol/l | Recommended only if LDL-C concentration is persistently above 3.5 mmol/l |
Primary heterozygous-familial hypercholesterolaemia | Recommended only if LDL-C concentration is persistently above 5.0 mmol/l | Recommended only if LDL-C concentration is persistently above 3.5 mmol/l | Recommended only if LDL-C concentration is persistently above 3.5 mmol/l |
1 - High risk of cardiovascular disease is defined as a history of any of the following: acute coronary syndrome (such as myocardial infarction or unstable angina requiring hospitalisation), coronary or other arterial revascularisation procedures, chronic heart disease, ischaemic stroke, peripheral arterial disease.
2 - Very high risk of cardiovascular disease is defined as recurrent cardiovascular events or cardiovascular events in more than 1 vascular bed (that is, polyvascular disease).
Abbreviations: CVD, cardiovascular disease; LDL-C, low-density lipoprotein cholesterol.
Reference:
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.